{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:49:58Z","timestamp":1751456998178,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":85,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071641873"},{"type":"electronic","value":"9781071641880"}],"license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4188-0_7","type":"book-chapter","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:03:07Z","timestamp":1729274587000},"page":"145-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies"],"prefix":"10.1007","author":[{"given":"Robby","family":"Engelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J et al (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 388:565\u2013575","journal-title":"Lancet"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY et al (2023) Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 14:2147","journal-title":"Nat Commun"},{"key":"7_CR3","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-revision-2_en.pdf. Accessed 7 Feb 2023"},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","volume":"131","author":"N Dimier","year":"2018","unstructured":"Dimier N, Delmar P, Ward C et al (2018) A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood 131:955\u2013962","journal-title":"Blood"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E et al (2022) Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 40:2901\u20132912","journal-title":"J Clin Oncol"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A et al (2024) Chronic lymphocytic Leukemia therapy guided by measurable residual disease. N Engl J Med 390:326\u2013337","journal-title":"N Engl J Med"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood.2020008164","volume":"137","author":"A-S Michallet","year":"2021","unstructured":"Michallet A-S, Letestu R, Le Garff-Tavernier M et al (2021) A fixed-duration, measurable residual disease\u2013guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood 137:1019\u20131023","journal-title":"Blood"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fon-2017-0442","volume":"14","author":"P Cramer","year":"2018","unstructured":"Cramer P, von Tresckow J, Bahlo J et al (2018) CLL2-BXX phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol 14:499\u2013513","journal-title":"Future Oncol"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bjh.18427","volume":"199","author":"T Munir","year":"2022","unstructured":"Munir T, Emmerson J, Hockaday A et al (2022) Obinutuzumab as consolidation after chemo-immunotherapy: results of the UK National Cancer Research Institute phase II\/III GALACTIC trial. Br J Haematol 199:707\u2013719","journal-title":"Br J Haematol"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/leu.2013.190","volume":"27","author":"AM Fink","year":"2013","unstructured":"Fink AM, Bottcher S, Ritgen M et al (2013) Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia 27:1949\u20131952","journal-title":"Leukemia"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","volume":"23","author":"AP Kater","year":"2022","unstructured":"Kater AP, Levin M-D, Dubois J et al (2022) Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 23:818\u2013828","journal-title":"Lancet Oncol"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T et al (2021) Ibrutinib Plus Venetoclax for first-line treatment of chronic lymphocytic Leukemia: primary analysis results from the minimal residual disease Cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 39:3853\u20133865","journal-title":"J Clin Oncol"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K et al (2019) Ibrutinib Plus Venetoclax in relapsed\/refractory chronic lymphocytic Leukemia: the CLARITY study. J Clin Oncol 37:2722\u20132729","journal-title":"J Clin Oncol"},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1200\/JCO.21.02321","volume":"40","author":"E Gin\u00e9","year":"2022","unstructured":"Gin\u00e9 E, de la Cruz F, Jim\u00e9nez Ubieto A et al (2022) Ibrutinib in combination with Rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a Multicenter, open-label, single-arm, phase II trial. J Clin Oncol 40:1196\u20131205","journal-title":"J Clin Oncol"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3324\/haematol.11267","volume":"93","author":"S Bottcher","year":"2008","unstructured":"Bottcher S, Ritgen M, Buske S et al (2008) Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 93:551\u2013559","journal-title":"Haematologica"},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","volume":"18","author":"S Bottcher","year":"2004","unstructured":"Bottcher S, Ritgen M, Pott C et al (2004) Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18:1637\u20131645","journal-title":"Leukemia"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A et al (2007) Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604\u2013611","journal-title":"Leukemia"},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood.2022017411","volume":"141","author":"PJ Hengeveld","year":"2023","unstructured":"Hengeveld PJ, van der Klift MY, Kolijn PM et al (2023) Detecting measurable residual disease beyond 10\u22124 by an IGHV leader-based NGS approach improves prognostic stratification in CLL. Blood 141:519\u2013528","journal-title":"Blood"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","volume":"33","author":"M Br\u00fcggemann","year":"2019","unstructured":"Br\u00fcggemann M, Kotrov\u00e1 M, Knecht H et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241\u20132253","journal-title":"Leukemia"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41375-019-0499-4","volume":"33","author":"H Knecht","year":"2019","unstructured":"Knecht H, Reigl T, Kotrov\u00e1 M et al (2019) Quality control and quantification in IG\/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33:2254\u20132265","journal-title":"Leukemia"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","volume":"33","author":"B Scheijen","year":"2019","unstructured":"Scheijen B, Meijers RWJ, Rijntjes J et al (2019) Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 33:2227\u20132240","journal-title":"Leukemia"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/bioinformatics\/btw634","volume":"33","author":"V Bystry","year":"2017","unstructured":"Bystry V, Reigl T, Krejci A et al (2017) ARResT\/Interrogate: an interactive immunoprofiler for IG\/TR NGS data. Bioinformatics 33:435\u2013437","journal-title":"Bioinformatics"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/sj.leu.2404416","volume":"20","author":"AC Rawstron","year":"2006","unstructured":"Rawstron AC, de Tute R, Jack AS et al (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 20:2102\u20132110","journal-title":"Leukemia"},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956\u2013964","journal-title":"Leukemia"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","volume":"26","author":"G Mateo","year":"2008","unstructured":"Mateo G, Montalban MA, Vidriales MB et al (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26:2737\u20132744","journal-title":"J Clin Oncol"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A et al (2016) A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 30:929\u2013936","journal-title":"Leukemia"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/leu.2009.140","volume":"23","author":"S Bottcher","year":"2009","unstructured":"Bottcher S, Stilgenbauer S, Busch R et al (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 23:2007\u20132017","journal-title":"Leukemia"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B et al (2017) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31:2094\u20132103","journal-title":"Leukemia"},{"key":"7_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","volume":"35","author":"R Letestu","year":"2021","unstructured":"Letestu R, Dahmani A, Boubaya M et al (2021) Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia 35:1597\u20131609","journal-title":"Leukemia"},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic Leukemia. N Engl J Med 374:311\u2013322","journal-title":"N Engl J Med"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM et al (2017) Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 18:230\u2013240","journal-title":"Lancet Oncol"},{"key":"7_CR32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17:768\u2013778","journal-title":"Lancet Oncol"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P et al (2019) Fixed duration of Venetoclax-rituximab in relapsed\/refractory chronic lymphocytic Leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol 37:269\u2013277","journal-title":"J Clin Oncol"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B et al (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic Leukemia. N Engl J Med 378:1107\u20131120","journal-title":"N Engl J Med"},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C et al (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24:1423\u20131433","journal-title":"Lancet Oncol"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS et al (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23:1031\u20131043","journal-title":"Lancet Oncol"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib-Rituximab or Chemoimmunotherapy for chronic lymphocytic Leukemia. N Engl J Med 381:432\u2013443","journal-title":"N Engl J Med"},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379:2517\u20132528","journal-title":"N Engl J Med"},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF et al (2022) Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140:839\u2013850","journal-title":"Blood"},{"key":"7_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S, Ritgen M, Fischer K et al (2012) Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980\u2013988","journal-title":"J Clin Oncol"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2018-03-839688","volume":"133","author":"AW Langerak","year":"2019","unstructured":"Langerak AW, Ritgen M, Goede V et al (2019) Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood 133:494\u2013497","journal-title":"Blood"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760","journal-title":"Blood"},{"key":"7_CR43","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2019001077","volume":"134","author":"PA Thompson","year":"2019","unstructured":"Thompson PA, Srivastava J, Peterson C et al (2019) Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134:1951\u20131959","journal-title":"Blood"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331","journal-title":"N Engl J Med"},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated Myeloma. N Engl J Med 378:518\u2013528","journal-title":"N Engl J Med"},{"key":"7_CR46","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for multiple Myeloma. N Engl J Med 375:754\u2013766","journal-title":"N Engl J Med"},{"key":"7_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab therapy for relapsed or refractory multiple Myeloma. N Engl J Med 373:621\u2013631","journal-title":"N Engl J Med"},{"key":"7_CR48","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T et al (2021) Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22:1582\u20131596","journal-title":"Lancet Oncol"},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397:2361\u20132371","journal-title":"Lancet"},{"key":"7_CR50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A et al (2021) Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 22:1378\u20131390","journal-title":"Lancet Oncol"},{"key":"7_CR51","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Bruggemann M, Monitillo L et al (2014) Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 28:1299\u20131307","journal-title":"Leukemia"},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Cedena MT, Puig N et al (2016) Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 127:3165\u20133174","journal-title":"Blood"},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Gutierrez NC, Rosinol L et al (2012) High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119:687\u2013691","journal-title":"Blood"},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva B, Martinez-Lopez J, Vidriales MB et al (2011) Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 29:1627\u20131633","journal-title":"J Clin Oncol"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales MB, Cervero J et al (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017\u20134023","journal-title":"Blood"},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM et al (2013) Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31:2540\u20132547","journal-title":"J Clin Oncol"},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB et al (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol 35:2900\u20132910","journal-title":"J Clin Oncol"},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA et al (2023) MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood 141:579\u2013591","journal-title":"Blood"},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA et al (2022) Minimal residual disease after autologous stem-cell transplant for patients with Myeloma: prognostic significance and the impact of Lenalidomide maintenance and molecular risk. J Clin Oncol 40:2889\u20132900","journal-title":"J Clin Oncol"},{"key":"7_CR60","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VH et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26:1986\u20132010","journal-title":"Leukemia"},{"key":"7_CR61","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"7_CR62","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271\u20132278","journal-title":"Blood"},{"key":"7_CR63","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215\u20133223","journal-title":"Blood"},{"key":"7_CR64","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","volume":"23","author":"A Kolstad","year":"2017","unstructured":"Kolstad A, Pedersen LB, Eskelund CW et al (2017) Molecular monitoring after autologous stem cell transplantation and Preemptive Rituximab treatment of molecular relapse; results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Marrow Transplant 23:428\u2013435","journal-title":"Biol Blood Marrow Transplant"},{"key":"7_CR65","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1182\/blood.2021014270","volume":"140","author":"S Ferrero","year":"2022","unstructured":"Ferrero S, Grimaldi D, Genuardi E et al (2022) Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood 140:1378\u20131389","journal-title":"Blood"},{"key":"7_CR66","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.23.00899","volume":"42","author":"E Hoster","year":"2024","unstructured":"Hoster E, Delfau-Larue MH, Macintyre E et al (2024) Predictive value of minimal residual disease for efficacy of Rituximab maintenance in mantle cell lymphoma: results from the European Mantle cell lymphoma elderly trial. J Clin Oncol 42:538\u2013549","journal-title":"J Clin Oncol"},{"key":"7_CR67","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A et al (2016) Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 101:336\u2013345","journal-title":"Haematologica"},{"key":"7_CR68","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B et al (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759\u20133766","journal-title":"Blood"},{"key":"7_CR69","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004\u20134013","journal-title":"Blood"},{"key":"7_CR70","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","volume":"20","author":"S Galimberti","year":"2014","unstructured":"Galimberti S, Luminari S, Ciabatti E et al (2014) Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res 20:6398\u20136405","journal-title":"Clin Cancer Res"},{"key":"7_CR71","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","volume":"126","author":"F Zohren","year":"2015","unstructured":"Zohren F, Bruns I, Pechtel S et al (2015) Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood 126:1407\u20131414","journal-title":"Blood"},{"key":"7_CR72","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.23.00838","volume":"42","author":"C Pott","year":"2024","unstructured":"Pott C, Jurinovic V, Trotman J et al (2024) Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study. J Clin Oncol 42:550\u2013561","journal-title":"J Clin Oncol"},{"key":"7_CR73","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers MH, Tonnissen E, Van Glabbeke M et al (2010) BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28:2246\u20132252","journal-title":"J Clin Oncol"},{"key":"7_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B et al (2016) Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 90:61\u201372","journal-title":"Cytometry B Clin Cytom"},{"key":"7_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cyto.a.22581","volume":"87","author":"T Kalina","year":"2015","unstructured":"Kalina T, Flores-Montero J, Lecrevisse Q et al (2015) Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 87:145\u2013156","journal-title":"Cytometry A"},{"key":"7_CR76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cyto.a.23901","volume":"97","author":"T Kalina","year":"2020","unstructured":"Kalina T (2020) Reproducibility of flow cytometry through standardization: opportunities and challenges. Cytometry A 97:137\u2013147","journal-title":"Cytometry A"},{"key":"7_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.09.008","volume":"475","author":"T Kalina","year":"2019","unstructured":"Kalina T, Brdickova N, Glier H et al (2019) Frequent issues and lessons learned from EuroFlow QA. J Immunol Methods 475:112520","journal-title":"J Immunol Methods"},{"key":"7_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.03.018","volume":"475","author":"S Bottcher","year":"2019","unstructured":"Bottcher S, van der Velden VHJ, Villamor N et al (2019) Lot-to-lot stability of antibody reagents for flow cytometry. J Immunol Methods 475:112294","journal-title":"J Immunol Methods"},{"key":"7_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.11.007","volume":"475","author":"M Novakova","year":"2019","unstructured":"Novakova M, Glier H, Brdickova N et al (2019) How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. J Immunol Methods 475:112388","journal-title":"J Immunol Methods"},{"key":"7_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112680","volume":"475","author":"H Glier","year":"2019","unstructured":"Glier H, Novakova M, Te Marvelde J et al (2019) Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. J Immunol Methods 475:112680","journal-title":"J Immunol Methods"},{"key":"7_CR81","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Bottcher S, Letestu R et al (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27:142\u2013149","journal-title":"Leukemia"},{"key":"7_CR82","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4049\/immunohorizons.2300066","volume":"7","author":"D Bhowmick","year":"2023","unstructured":"Bhowmick D, Lowe SK, Ratliff ML (2023) Side-by-side comparison of compensation beads used in polychromatic flow cytometry. ImmunoHorizons 7:819\u2013833","journal-title":"ImmunoHorizons"},{"key":"7_CR83","doi-asserted-by":"publisher","unstructured":"Shevchenko Y, Lurje I, Tacke F et al (2024) Fluorochrome-dependent specific changes in spectral profiles using different compensation beads or primary cells in full spectrum cytometry. Cytometry A.; epub ehead of print;. https:\/\/doi.org\/10.1002\/cyto.a.24836","DOI":"10.1002\/cyto.a.24836"},{"key":"7_CR84","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1182\/blood.V91.7.2588","volume":"91","author":"C Bomberger","year":"1998","unstructured":"Bomberger C, Singh-Jairam M, Rodey G et al (1998) Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91:2588\u20132600","journal-title":"Blood"},{"key":"7_CR85","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M et al (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93:431\u2013438","journal-title":"Haematologica"}],"container-title":["Methods in Molecular Biology","Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4188-0_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T19:02:24Z","timestamp":1729278144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4188-0_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"ISBN":["9781071641873","9781071641880"],"references-count":85,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4188-0_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"19 October 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}